SynaptixBio
PrivateLast Round
Grant
Aug 22, 2024
Total Funding Raised
$19.88M
Company Overview
SynaptixBio is a biotechnology company that develops gene silencing therapies for severe leukodystrophies and other childhood neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SynaptixBio Comparables
Compare SynaptixBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vico Therapeutics | 78% | |
| Velvio GmbH | 78% | |
| Sinfonia Biotherapeutics | 71% | |
SynaptixBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 22, 2024 | ||||
| Grant | Dec 23, 2023 | ||||
| Seed | Apr 28, 2023 | ||||
| Seed | Apr 1, 2021 |
SynaptixBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2024
$2.6M grant received from Innovate UK.
SynaptixBio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about SynaptixBio's valuation, stock price, and market status.